HBPCF (Helix BioPharma) Total Inventories: $0.00 Mil (As of Apr. 2026)


HBPCF Helix BioPharma Corp HBPCF
28 GF Score
Price $1.71
View Full Analysis

What is Helix BioPharma Total Inventories?

Helix BioPharma HBPCF 28 Total Inventories is $0.00 Mil as of Apr. 2026. GuruFocus rates HBPCF with a GF Score™ of 28/100.

Helix BioPharma's total inventories for the quarter that ended in Apr. 2026 was $0.00 Mil. Helix BioPharma's average total inventories from the quarter that ended in Jan. 2026 to the quarter that ended in Apr. 2026 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Helix BioPharma's Net-Net Working Capital per share for the quarter that ended in Apr. 2026 was $-0.04.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Helix BioPharma  (OTCPK:HBPCF) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Helix BioPharma's Net-Net Working Capital Per Share for the quarter that ended in Apr. 2026 is

Net-Net Working Capital Per Share (Q: Apr. 2026 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(2.066+0.75 * 0+0.5 * 0-4.866
-0-0)/76.378
=-0.04

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Helix BioPharma's Days Inventory for the three months ended in Apr. 2026 is calculated as:

Days Inventory=Average Total Inventories (Q: Apr. 2026 )/Cost of Goods Sold (Q: Apr. 2026 )*Days in Period
=0/0*365 / 4
=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Helix BioPharma's Inventory Turnover for the quarter that ended in Apr. 2026 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Apr. 2026 ) / Average Total Inventories (Q: Apr. 2026 )
=0 / 0
=N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Helix BioPharma's Inventory to Revenue for the quarter that ended in Apr. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Apr. 2026 ) / Revenue (Q: Apr. 2026 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Helix BioPharma Total Inventories Related Terms

Helix BioPharma Total Inventories Historical Data

* Premium members only.

The historical data trend for Helix BioPharma's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helix BioPharma Total Inventories Chart

Helix BioPharma Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Helix BioPharma Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HBPCF
28GF Score
Helix BioPharma Corp HBPCF
Total Inventories is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Helix BioPharma Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Frequently Asked Questions Learn more about Total Inventories →
What does a Total Inventories of $0.00 Mil mean?
Helix BioPharma (HBPCF) has a Total Inventories of $0.00 Mil as of Apr. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Helix BioPharma and its competitors.
Is Helix BioPharma's Total Inventories too high?
Helix BioPharma's current Total Inventories is $0.00 Mil. Overall, Helix BioPharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's Total Inventories compare to VRTX and REGN?
Helix BioPharma's Total Inventories of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Helix BioPharma and its competitors. Helix BioPharma's current Total Inventories is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current Total Inventories of $0.00 Mil. The current Total Inventories is $0.00 Mil. Helix BioPharma's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current Total Inventories is $0.00 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helix BioPharma Business Description

Other Exchanges HBP0:GermanyHBP:Canada
Address 40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
28GF Score

Get the complete analysis for HBPCF

Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.71
Price